Drug Trial Radar · NCT04901117
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,300
Planned (sponsor's estimate)
Start
Jun 2021
Primary completion
Jun 2023
Study completion Aug 2023
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Affiliated Hospital of Qingdao University; The People's Hospital of Guangrao; Weihai Municipal Hospital; Shandong Province Third hospital; Taian City Central Hospital; Jining No.2 People's Hospital; Maternity and Child Care Health Center of Dezhou; Zoucheng People's Hospital; Heze Municipal 3rd people's hospital; Yuncheng Chengxin Hospital; Peking University Care Luzhong Hospital; Qihe County City Hospital; Weifang People's Hospital; Qilu Hospital of Shandong University; Shandong Electric Power Central Hospital
- First posted
- May 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
Conditions
- Helicobacter Pylori Infection
Interventions
AmoxicillinDrug
Use according to the drug combination options selected by each center.
ClarithromycinDrug
Use according to the drug combination options selected by each center.
TetracyclineDrug
Use according to the drug combination options selected by each center.
MetronidazoleDrug
Use according to the drug combination options selected by each center.
Bismuth Potassium CitrateDrug
Use according to the drug combination options selected by each center.
Colloidal Bismuth PectinDrug
Use according to the drug combination options selected by each center.
Vonoprazan fumarateDrug
Use according to the drug combination options selected by each center.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication rateTime frame: Immediately after follow-up check.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu hosipital
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.